phosphorylcholine has been researched along with Atherogenesis in 33 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phosphorylcholine (PC) is one of the main oxLDL epitopes playing a central role in atherosclerosis, due to its atherogenic and proinflammatory effects." | 8.12 | Phosphorylcholine Monoclonal Antibody Therapy Decreases Intraplaque Angiogenesis and Intraplaque Hemorrhage in Murine Vein Grafts. ( Baganha, F; de Jong, RCM; de Vries, MR; Delibegovic, M; Jukema, JW; Peters, HAB; Pettersson, K; Quax, PHA; Sluiter, TJ; van Alst, LA, 2022) |
| "Natural immunoglobulin M antibodies specific for phosphorylcholine (anti-PC) have been implicated in atherosclerosis." | 7.76 | Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. ( de Faire, U; Fiskesund, R; Frostegård, J; Hallmans, G; Stegmayr, B; Vikström, M; Weinehall, L, 2010) |
| "Natural antibodies specific for phosphorylcholine (anti-PC) have been implicated as protective factors in atherosclerosis." | 7.75 | Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. ( Berglund, G; Dahlbom, I; de Faire, U; Frostegård, J; Grönlund, H; Hedblad, B; Sjöberg, BG; Su, J; Wikström, M, 2009) |
| "The present study evaluated the effect of phosphorylcholine (PC) immunization on the extent of experimental atherosclerosis." | 7.74 | Phosphorylcholine-targeting immunization reduces atherosclerosis. ( Caligiuri, G; Delignat, S; Gaston, AT; Kaveri, SV; Khallou-Laschet, J; Kohler, HV; Mandet, C; Nicoletti, A; Vandaele, M, 2007) |
| "Atherosclerosis is an inflammatory condition characterised by an abundance of activated immunocompetent cells in plaques which cause cardiovascular disease (CVD) when they rupture." | 6.46 | Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. ( Frostegård, J, 2010) |
| "Phosphorylcholine (PC) is an important pro-inflammatory damage-associated molecular pattern." | 5.62 | Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. ( Bergman, A; Dahlbom, I; de Jong, RCM; de Vries, MR; Ewing, MM; Frostegård, J; Jukema, JW; Karabina, SAP; Karper, JC; Kuiper, J; MacArthur, MR; Mitchell, JR; Ninio, E; Nordzell, M; Peters, EAB; Pettersson, K; Quax, PHA; Sexton, D, 2021) |
| "Phosphorylcholine (PC) is one of the main oxLDL epitopes playing a central role in atherosclerosis, due to its atherogenic and proinflammatory effects." | 4.12 | Phosphorylcholine Monoclonal Antibody Therapy Decreases Intraplaque Angiogenesis and Intraplaque Hemorrhage in Murine Vein Grafts. ( Baganha, F; de Jong, RCM; de Vries, MR; Delibegovic, M; Jukema, JW; Peters, HAB; Pettersson, K; Quax, PHA; Sluiter, TJ; van Alst, LA, 2022) |
| "Studies have reported an association between low levels of natural immunoglobulin M antibodies against phosphorylcholine(IgM anti-PC) and worse prognosis in patients with coronary artery disease (CAD)." | 3.91 | IgM antibodies against phosphorylcholine measured early after acute ST-elevation myocardial infarction in relation to atherosclerotic disease burden and long-term clinical outcome. ( Aksnes, TA; Andersen, GØ; Arnesen, H; Eritsland, J; Knudsen, EC; Seljeflot, I, 2019) |
| "IgM antibodies against phosphorylcholine (anti-PC) are negatively associated with atherosclerosis, cardiovascular disease (CVD) and systemic lupus erythematosus (SLE), where the risk of CVD and atherosclerosis is high." | 3.88 | IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors. ( Ajeganova, S; Frostegård, J; Gillgren, P; Liu, A; Lundström, SL; Rahman, M; Steuer, J; Sun, J; Zhang, B; Zubarev, RA, 2018) |
| "We here study antibodies against phosphorylcholine (anti-PC) which we reported to be inversely associated with atherosclerosis, cardiovascular disease (CVD), and autoimmune conditions." | 3.85 | Antibodies against Phosphorylcholine among New Guineans Compared to Swedes: An Aspect of the Hygiene/Missing Old Friends Hypothesis. ( Frostegård, J; Lindblad, U; Lindeberg, S; Råstam, L; Tao, W, 2017) |
| "Natural immunoglobulin M antibodies specific for phosphorylcholine (anti-PC) have been implicated in atherosclerosis." | 3.76 | Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. ( de Faire, U; Fiskesund, R; Frostegård, J; Hallmans, G; Stegmayr, B; Vikström, M; Weinehall, L, 2010) |
| "Natural antibodies specific for phosphorylcholine (anti-PC) have been implicated as protective factors in atherosclerosis." | 3.75 | Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. ( Berglund, G; Dahlbom, I; de Faire, U; Frostegård, J; Grönlund, H; Hedblad, B; Sjöberg, BG; Su, J; Wikström, M, 2009) |
| "The present study evaluated the effect of phosphorylcholine (PC) immunization on the extent of experimental atherosclerosis." | 3.74 | Phosphorylcholine-targeting immunization reduces atherosclerosis. ( Caligiuri, G; Delignat, S; Gaston, AT; Kaveri, SV; Khallou-Laschet, J; Kohler, HV; Mandet, C; Nicoletti, A; Vandaele, M, 2007) |
| "To assess the effect of irinotecan-eluting stents (IS) on neointimal growth in the aortas of hypercholesterolemic rabbits and to determine other local histopathological effects such as necrosis, fibrin, and inflammatory reaction." | 3.73 | Irinotecan-eluting stents inhibited neointimal proliferation in hypercholesterolemic rabbit aortas. ( Berrocal, DH; Gelpi, RJ; González, GE; Grinfeld, LR; Morales, C, 2006) |
| "Atherosclerosis is the main cause of CVD in the general population, and in SLE, increased atherosclerosis, especially the prevalence of atherosclerotic plaques, has been demonstrated." | 3.01 | Systemic lupus erythematosus and cardiovascular disease. ( Frostegård, J, 2023) |
| "Atherosclerosis is an inflammatory condition characterised by an abundance of activated immunocompetent cells in plaques which cause cardiovascular disease (CVD) when they rupture." | 2.46 | Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. ( Frostegård, J, 2010) |
| "Atherosclerosis is a chronic inflammatory disease characterized by the presence of activated immune-competent cells in the lesions, producing mainly proinflammatory cytokines." | 2.45 | Natural antibodies against phosphorylcholine in cardiovascular disease. ( de Faire, U; Frostegård, J, 2009) |
| "Phosphorylcholine (PC) is an important pro-inflammatory damage-associated molecular pattern." | 1.62 | Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. ( Bergman, A; Dahlbom, I; de Jong, RCM; de Vries, MR; Ewing, MM; Frostegård, J; Jukema, JW; Karabina, SAP; Karper, JC; Kuiper, J; MacArthur, MR; Mitchell, JR; Ninio, E; Nordzell, M; Peters, EAB; Pettersson, K; Quax, PHA; Sexton, D, 2021) |
| "Robust deposition of IgM within atherosclerotic plaques could also be readily observed in both control and experimental mice." | 1.43 | Atherosclerosis Susceptibility in Mice Is Independent of the V1 Immunoglobulin Heavy Chain Gene. ( Binder, CJ; Centa, M; Gruber, S; Hansson, GK; Johansson, DK; Ketelhuth, DF; Malin, S; Nilsson, D; Polyzos, KA, 2016) |
| "We studied whether carotid atherosclerosis, RA disease measures, or potential cardiovascular biomarkers influenced the incidence of CVD in an RA inception cohort." | 1.38 | Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study. ( Ajeganova, S; de Faire, U; Frostegård, J; Hafström, I; Jogestrand, T, 2012) |
| "Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of oxidized lipoproteins and apoptotic cells." | 1.35 | Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. ( Bäckhed, F; Binder, CJ; Choi, J; Chou, MY; Corr, M; Fogelstrand, L; Hansen, LF; Hartvigsen, K; Hörkkö, S; Miller, YI; Perkmann, T; Shaw, PX; Witztum, JL; Woelkers, D, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (27.27) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 8 (24.24) | 2.80 |
| Authors | Studies |
|---|---|
| Frostegård, J | 16 |
| Baganha, F | 1 |
| Sluiter, TJ | 1 |
| de Jong, RCM | 2 |
| van Alst, LA | 1 |
| Peters, HAB | 1 |
| Jukema, JW | 2 |
| Delibegovic, M | 1 |
| Pettersson, K | 2 |
| Quax, PHA | 2 |
| de Vries, MR | 2 |
| Ewing, MM | 1 |
| MacArthur, MR | 1 |
| Karper, JC | 1 |
| Peters, EAB | 1 |
| Nordzell, M | 1 |
| Karabina, SAP | 1 |
| Sexton, D | 1 |
| Dahlbom, I | 2 |
| Bergman, A | 1 |
| Mitchell, JR | 1 |
| Kuiper, J | 1 |
| Ninio, E | 1 |
| Samal, SK | 1 |
| Fröbert, O | 1 |
| Kindberg, J | 1 |
| Stenvinkel, P | 1 |
| Ajeganova, S | 4 |
| Andersson, MLE | 1 |
| Hafström, I | 4 |
| Momtazi-Borojeni, AA | 1 |
| Abdollahi, E | 1 |
| Jaafari, MR | 1 |
| Banach, M | 1 |
| Watts, GF | 1 |
| Sahebkar, A | 1 |
| Sun, J | 1 |
| Lundström, SL | 1 |
| Zhang, B | 1 |
| Zubarev, RA | 1 |
| Steuer, J | 1 |
| Gillgren, P | 1 |
| Rahman, M | 2 |
| Liu, A | 2 |
| Que, X | 1 |
| Hung, MY | 1 |
| Yeang, C | 1 |
| Gonen, A | 1 |
| Prohaska, TA | 1 |
| Sun, X | 1 |
| Diehl, C | 1 |
| Määttä, A | 1 |
| Gaddis, DE | 1 |
| Bowden, K | 1 |
| Pattison, J | 1 |
| MacDonald, JG | 1 |
| Ylä-Herttuala, S | 1 |
| Mellon, PL | 1 |
| Hedrick, CC | 1 |
| Ley, K | 1 |
| Miller, YI | 2 |
| Glass, CK | 1 |
| Peterson, KL | 1 |
| Binder, CJ | 4 |
| Tsimikas, S | 1 |
| Witztum, JL | 3 |
| Knudsen, EC | 1 |
| Seljeflot, I | 1 |
| Aksnes, TA | 1 |
| Eritsland, J | 1 |
| Arnesen, H | 1 |
| Andersen, GØ | 1 |
| Newling, M | 1 |
| Sritharan, L | 1 |
| van der Ham, AJ | 1 |
| Hoepel, W | 1 |
| Fiechter, RH | 1 |
| de Boer, L | 1 |
| Zaat, SAJ | 1 |
| Bisoendial, RJ | 1 |
| Baeten, DLP | 1 |
| Everts, B | 1 |
| den Dunnen, J | 1 |
| López, P | 1 |
| Rodríguez-Carrio, J | 1 |
| Martínez-Zapico, A | 1 |
| Pérez-Álvarez, ÁI | 1 |
| Benavente, L | 1 |
| Caminal-Montero, L | 1 |
| Suárez, A | 1 |
| Sobel, M | 1 |
| Moreno, KI | 1 |
| Yagi, M | 1 |
| Kohler, TR | 1 |
| Tang, GL | 1 |
| Clowes, AW | 1 |
| Zhou, XH | 1 |
| Eugenio, E | 1 |
| Agrawal, A | 1 |
| Gang, TB | 1 |
| Rusiñol, AE | 1 |
| Frostegård, AG | 2 |
| Su, J | 2 |
| Hua, X | 1 |
| Vikström, M | 2 |
| de Faire, U | 5 |
| Centa, M | 1 |
| Gruber, S | 1 |
| Nilsson, D | 1 |
| Polyzos, KA | 1 |
| Johansson, DK | 1 |
| Hansson, GK | 1 |
| Ketelhuth, DF | 1 |
| Malin, S | 1 |
| Sing, S | 1 |
| Golabkesh, Z | 1 |
| Fiskesund, R | 2 |
| Gustafsson, T | 1 |
| Jogestrand, T | 3 |
| Tao, W | 1 |
| Råstam, L | 1 |
| Lindblad, U | 1 |
| Lindeberg, S | 1 |
| Sjöberg, BG | 1 |
| Grönlund, H | 1 |
| Wikström, M | 1 |
| Hedblad, B | 1 |
| Berglund, G | 1 |
| Chou, MY | 1 |
| Fogelstrand, L | 1 |
| Hartvigsen, K | 2 |
| Hansen, LF | 1 |
| Woelkers, D | 1 |
| Shaw, PX | 1 |
| Choi, J | 1 |
| Perkmann, T | 1 |
| Bäckhed, F | 1 |
| Hörkkö, S | 1 |
| Corr, M | 1 |
| Epand, RF | 1 |
| Mishra, VK | 1 |
| Palgunachari, MN | 1 |
| Anantharamaiah, GM | 1 |
| Epand, RM | 1 |
| Stegmayr, B | 1 |
| Hallmans, G | 1 |
| Weinehall, L | 1 |
| Kikuchi, T | 1 |
| El Shikh, MM | 1 |
| El Sayed, RM | 1 |
| Purkall, DB | 1 |
| Elaasser, MM | 1 |
| Sarraf, A | 1 |
| Barbour, SE | 1 |
| Schenkein, HA | 1 |
| Tew, JG | 1 |
| Ehrnfelt, C | 1 |
| Alizadeh, R | 1 |
| Rohani, M | 1 |
| Faria-Neto, JR | 1 |
| Chyu, KY | 1 |
| Li, X | 1 |
| Dimayuga, PC | 1 |
| Ferreira, C | 1 |
| Yano, J | 1 |
| Cercek, B | 1 |
| Shah, PK | 1 |
| Berrocal, DH | 1 |
| González, GE | 1 |
| Morales, C | 1 |
| Gelpi, RJ | 1 |
| Grinfeld, LR | 1 |
| Huang, MS | 1 |
| Morony, S | 1 |
| Lu, J | 1 |
| Zhang, Z | 1 |
| Bezouglaia, O | 1 |
| Tseng, W | 1 |
| Tetradis, S | 1 |
| Demer, LL | 1 |
| Tintut, Y | 1 |
| Caligiuri, G | 1 |
| Khallou-Laschet, J | 1 |
| Vandaele, M | 1 |
| Gaston, AT | 1 |
| Delignat, S | 1 |
| Mandet, C | 1 |
| Kohler, HV | 1 |
| Kaveri, SV | 1 |
| Nicoletti, A | 1 |
4 reviews available for phosphorylcholine and Atherogenesis
| Article | Year |
|---|---|
Systemic lupus erythematosus and cardiovascular disease.
Topics: Antibodies, Antiphospholipid; Atherosclerosis; Cardiovascular Diseases; Humans; Inflammation; Lupus | 2023 |
Recognition functions of pentameric C-reactive protein in cardiovascular disease.
Topics: Animals; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Complement Activation; Gene E | 2014 |
Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease.
Topics: Animals; Atherosclerosis; Autoantibodies; Cardiovascular Diseases; Humans; Lipoproteins, LDL; Models | 2010 |
Natural antibodies against phosphorylcholine in cardiovascular disease.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Humans; Immunoglobulin M; Lipoproteins, LDL; Lupu | 2009 |
29 other studies available for phosphorylcholine and Atherogenesis
| Article | Year |
|---|---|
Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Humans; Immunoglobulin G; Immunoglobulin M; Infla | 2022 |
Phosphorylcholine Monoclonal Antibody Therapy Decreases Intraplaque Angiogenesis and Intraplaque Hemorrhage in Murine Vein Grafts.
Topics: Animals; Antibodies, Monoclonal; Atherosclerosis; Hemorrhage; Humans; Male; Mice; Neovascularization | 2022 |
Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Atherosclerosis; Cardiovascular Diseases; | 2021 |
Potential natural immunization against atherosclerosis in hibernating bears.
Topics: Animals; Antibodies, Antiphospholipid; Atherosclerosis; Hibernation; Immunity, Innate; Immunoglobuli | 2021 |
Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.
Topics: Aged; Arthritis, Rheumatoid; Atherosclerosis; Autoantibodies; Cardiovascular Diseases; Female; Human | 2021 |
Negatively-charged Liposome Nanoparticles Can Prevent Dyslipidemia and Atherosclerosis Progression in the Rabbit Model.
Topics: Animals; Atherosclerosis; Cholesterol; Dimyristoylphosphatidylcholine; Dyslipidemias; Liposomes; Nan | 2022 |
IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors.
Topics: Atherosclerosis; Autoimmunity; Case-Control Studies; Cells, Cultured; Dendritic Cells; Female; Flow | 2018 |
Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.
Topics: Animals; Aortic Valve Stenosis; Apoptosis; Atherosclerosis; Cholesterol; Disease Progression; Fatty | 2018 |
IgM antibodies against phosphorylcholine measured early after acute ST-elevation myocardial infarction in relation to atherosclerotic disease burden and long-term clinical outcome.
Topics: Aged; Antibodies, Anti-Idiotypic; Atherosclerosis; Coronary Artery Disease; Female; Follow-Up Studie | 2019 |
C-Reactive Protein Promotes Inflammation through FcγR-Induced Glycolytic Reprogramming of Human Macrophages.
Topics: Atherosclerosis; C-Reactive Protein; Cells, Cultured; Cellular Reprogramming; Cytokines; Glycolysis; | 2019 |
IgM anti-phosphorylcholine antibodies associate with senescent and IL-17+ T cells in SLE patients with a pro-inflammatory lipid profile.
Topics: Adult; Atherosclerosis; Autoantibodies; Biomarkers; Carotid Arteries; Female; Humans; Immunoglobulin | 2020 |
Low levels of a natural IgM antibody are associated with vein graft stenosis and failure.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Biomarkers; Constriction, Pathologic; Down-Regulation; Fem | 2013 |
Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development.
Topics: Adult; Antibodies; Apoptosis; Atherosclerosis; Cardiolipins; Carotid Intima-Media Thickness; Enzyme- | 2014 |
Atherosclerosis Susceptibility in Mice Is Independent of the V1 Immunoglobulin Heavy Chain Gene.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; B-Lymphocytes; Disease Models, | 2016 |
IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms.
Topics: Adult; Apoptosis; Atherosclerosis; B-Lymphocytes; Biomarkers; Carotid Intima-Media Thickness; CD3 Co | 2016 |
Antibodies against Phosphorylcholine among New Guineans Compared to Swedes: An Aspect of the Hygiene/Missing Old Friends Hypothesis.
Topics: Adult; Antibodies; Atherosclerosis; Autoimmune Diseases; Cohort Studies; Female; Humans; Hygiene Hyp | 2017 |
[Small fatty substances may be of great importance in the development of atherosclerosis].
Topics: Antibodies; Atherosclerosis; Humans; Inflammation; Malondialdehyde; Phosphorylcholine | 2017 |
Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol; Cohort Studies; Female; | 2009 |
Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans.
Topics: Adoptive Transfer; Animals; Antibody Affinity; Antibody Formation; Antibody Specificity; Apoptosis; | 2009 |
Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Calorimetry, Differential Scanning; Lipid Bilayers; Lipid | 2009 |
Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden.
Topics: Adult; Aged; Antibodies; Atherosclerosis; Case-Control Studies; Female; Humans; Immunoglobulin M; Ma | 2010 |
Anti-phosphorylcholine-opsonized low-density lipoprotein promotes rapid production of proinflammatory cytokines by dendritic cells and natural killer cells.
Topics: Aggregatibacter actinomycetemcomitans; Analysis of Variance; Antibodies; Antigens, CD; Atheroscleros | 2010 |
Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset--a prospective cohort study.
Topics: Aged; Apolipoproteins; Arthritis, Rheumatoid; Atherosclerosis; Autoantibodies; Carotid Artery Diseas | 2011 |
Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study.
Topics: Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Carotid Arteries; Carotid | 2012 |
Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Apolipoproteins E; Atherosclerosis; Car | 2006 |
Irinotecan-eluting stents inhibited neointimal proliferation in hypercholesterolemic rabbit aortas.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Camptothecin; Cell Proliferation; Dietary Fats; Disease | 2006 |
Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts.
Topics: Animals; Atherosclerosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; DNA-Binding Pro | 2007 |
Phosphorylcholine-targeting immunization reduces atherosclerosis.
Topics: Animals; Antibodies; Antibody Formation; Atherosclerosis; B-Lymphocytes; Cells, Cultured; Female; He | 2007 |
Promise of immune modulation to inhibit atherogenesis.
Topics: Animals; Antibodies; Atherosclerosis; Epitopes; Hemocyanins; Humans; Immunization; Lipoproteins, LDL | 2007 |